Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS-2M: Cabotegravir + Rilpivirine Every 8 Weeks vs Every 4 Weeks in HIV-1
NCT03299049Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Oct 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Oct 2017; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03299049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299049.